QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:KZIA

Kazia Therapeutics - KZIA News Headlines

$1.67
-0.13 (-7.22%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.67
$1.83
50-Day Range
$1.67
$6.05
52-Week Range
$1.63
$12.28
Volume
354,431 shs
Average Volume
268,106 shs
Market Capitalization
$22.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Get Kazia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

KZIA Media Mentions By Week

KZIA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KZIA
News Sentiment

0.04

0.35

Average
Medical
News Sentiment

KZIA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KZIA Articles
This Week

9

1

KZIA Articles
Average Week



SourceHeadline
proactiveinvestors.com.au logoKazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference
proactiveinvestors.com.au - August 7 at 10:48 PM
proactiveinvestors.com logoKazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma
proactiveinvestors.com - August 7 at 10:48 PM
finance.yahoo.com logoKazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
finance.yahoo.com - August 5 at 4:57 PM
nasdaq.com logoKazia Reports Promising Interim Data From Phase I Trial Of Paxalisib
nasdaq.com - August 5 at 11:56 AM
markets.businessinsider.com logoBiotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
markets.businessinsider.com - August 5 at 11:56 AM
finance.yahoo.com logoKAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
finance.yahoo.com - August 5 at 11:56 AM
MarketBeat logoKazia Therapeutics (NASDAQ:KZIA) Rating Lowered to Hold at Maxim Group
americanbankingnews.com - August 3 at 5:38 AM
MarketBeat logoKazia Therapeutics (NASDAQ:KZIA) Downgraded to Neutral at HC Wainwright
americanbankingnews.com - August 3 at 4:54 AM
benzinga.com logoKazia Shares Tumble After Update From Pivotal Brain Tumor Trial
benzinga.com - August 1 at 7:07 AM
finance.yahoo.com logoKazia Therapeutics (ASX:KZA) Is In A Strong Position To Grow Its Business
finance.yahoo.com - July 17 at 10:35 PM
finance.yahoo.com logoKAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
finance.yahoo.com - July 12 at 12:45 PM
ca.proactiveinvestors.com logoKazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer
ca.proactiveinvestors.com - July 11 at 9:42 PM
proactiveinvestors.com.au logoKazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer
proactiveinvestors.com.au - July 7 at 12:06 AM
nasdaq.com logoFDA Awards Rare Pediatric Disease Designation To Kazia's Paxalisib For Childhood Brain Cancer
nasdaq.com - July 6 at 7:06 PM
marketwatch.com logoKazia Therapeutics Shares Rise Premarket After Key FDA Designation >KZIA
marketwatch.com - July 6 at 7:06 PM
finance.yahoo.com logoUS FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
finance.yahoo.com - July 6 at 7:34 AM
proactiveinvestors.com logoKazia Therapeutics continues to make good progress on cancer treatment assets
proactiveinvestors.com - June 29 at 11:45 PM
nasdaq.com logoFDA Awards Orphan Drug Designation To Kazia's Paxalisib For Rare Form Of Childhood Brain Cancer
nasdaq.com - June 17 at 4:46 PM
msn.com logoKazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug
msn.com - June 17 at 4:46 PM
seekingalpha.com logoKazia stock jumps on FDA orphan drug designation for treatment in childhood brain cancer
seekingalpha.com - June 17 at 4:46 PM
finance.yahoo.com logoUS FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
finance.yahoo.com - June 17 at 4:46 PM
proactiveinvestors.com logoKazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib
proactiveinvestors.com - June 17 at 12:50 AM
proactiveinvestors.com logoKazia Therapeutics welcomes presentation of positive paxalisib data at international symposium
proactiveinvestors.com - June 13 at 8:20 PM
finance.yahoo.com logoPOSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
finance.yahoo.com - June 13 at 7:59 AM
finance.yahoo.com logoQuite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
finance.yahoo.com - June 8 at 10:39 PM
ca.proactiveinvestors.com logoKazia onto next chapter in Phase 2 brain metastases trial
ca.proactiveinvestors.com - June 7 at 11:42 PM
proactiveinvestors.com logoKazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort
proactiveinvestors.com - June 7 at 11:42 PM
finance.yahoo.com logoPHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
finance.yahoo.com - June 7 at 9:19 AM
nasdaq.com logoKazia Therapeutics Reports Final Data From Phase II Study Of Paxalisib - Quick Facts
nasdaq.com - June 3 at 10:41 AM
finance.yahoo.com logoKAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
finance.yahoo.com - June 3 at 10:41 AM
finance.yahoo.com logoGBM AGILE OPENS TO PAXALISIB IN EUROPE
finance.yahoo.com - May 31 at 9:55 AM
finance.yahoo.com logoKazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
finance.yahoo.com - May 26 at 8:33 AM
finance.yahoo.com logoKAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE
finance.yahoo.com - May 17 at 8:54 AM
finance.yahoo.com logoInvesting in Kazia Therapeutics (ASX:KZA) three years ago would have delivered you a 69% gain
finance.yahoo.com - May 16 at 10:53 PM
proactiveinvestors.com logoKazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
proactiveinvestors.com - May 1 at 10:37 PM
proactiveinvestors.com logoKazia Therapeutics establishes ‘at the market’ equity program
proactiveinvestors.com - April 25 at 11:06 PM
proactiveinvestors.com logoKazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference
proactiveinvestors.com - April 20 at 11:18 PM
finance.yahoo.com logoTWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
finance.yahoo.com - April 8 at 11:38 AM
finance.yahoo.com logoKAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURS
finance.yahoo.com - April 8 at 11:38 AM
proactiveinvestors.com logoKazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans
proactiveinvestors.com - April 8 at 1:23 AM
finance.yahoo.com logoKazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
finance.yahoo.com - March 30 at 9:53 AM
finance.yahoo.com logoKAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETING
finance.yahoo.com - March 21 at 11:30 AM
finance.yahoo.com logoPHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENT
finance.yahoo.com - February 28 at 12:44 PM
proactiveinvestors.com.au logoKazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma
proactiveinvestors.com.au - February 28 at 1:02 AM
proactiveinvestors.com logoKazia Therapeutics delivers on plans with two promising assets in human trials
proactiveinvestors.com - February 24 at 10:14 AM
finance.yahoo.com logoWe Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
finance.yahoo.com - February 7 at 6:47 PM
finance.yahoo.com logoKAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE
finance.yahoo.com - February 7 at 8:45 AM
finance.yahoo.com logoKAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
finance.yahoo.com - January 25 at 10:08 AM
nasdaq.com logoKazia Therapeutics Limited American Depositary Shares (KZIA)
nasdaq.com - January 16 at 11:42 PM
finance.yahoo.com logoKAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
finance.yahoo.com - January 7 at 10:13 AM
Get Kazia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:KZIA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.